Head-to-head · checked 2026-08-07
Retatrutide vs Ozempic: why this comparison isn't quite what it seems
Ozempic and Wegovy contain the same drug — semaglutide — at different doses for different licensed uses. Understanding that distinction matters more than the retatrutide comparison itself.
Ozempic isn't a weight-loss drug — officially
This is the detail most "vs Ozempic" comparisons skip.
What Ozempic is actually licensed for
Ozempic is semaglutide licensed in the UK for type 2 diabetes, at a lower maximum dose than Wegovy. It is not licensed for weight management — weight loss is a secondary effect, and any weight-loss use is off-label. Wegovy is the same active ingredient, licensed specifically for weight loss at a higher dose. If your interest is weight loss specifically, Wegovy is the on-label comparison; Ozempic is a diabetes medicine that happens to produce weight loss as a side effect.
| Ozempic (semaglutide) | Retatrutide | |
|---|---|---|
| UK licensed indication | Type 2 diabetes (weight loss is off-label) | None — not licensed for any use |
| Receptors targeted | GLP-1 only | GLP-1 + GIP + glucagon |
| Weight loss (in its licensed context) | Secondary effect, generally lower than Wegovy's on-label dose | Up to 30.3% (TRIUMPH-1, phase 3, obesity trial) |
| UK status | Licensed for diabetes & available | Not licensed anywhere — phase 3 only |
The practical takeaway today
If weight loss is your actual goal, Wegovy — not Ozempic — is the correctly-licensed semaglutide comparison, and it's already available through regulated UK providers. Retatrutide's trial numbers don't change either drug's UK availability today.
Retatrutide vs WegovyThe on-label weight-loss comparison
Retatrutide UK statusFull evidence & regulatory record
Compare Wegovy providersWegoCompare →